Par Health recalls two lots of dexmedetomidine infusion due to particulate contamination

Par Health announced a voluntary recall of two lots of its dexmedetomidine HCl in 0.9% sodium chloride injection, which is used for intravenous sedation.

The recall was initiated after testing identified particulate matter, described as cellulose or stopper material, in the product.

Regulators warned that such particles could potentially cause life‑threatening events such as pulmonary emboli, vascular occlusions or vein inflammation, although no adverse events have been reported to date.

The recall is being carried out at the hospital level, and the company has not received any reports of related health issues.